Cargando…

Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson’s Rats

Prolonged pulsatile administration of Levodopa (L-dopa) can generate L-dopa–induced dyskinesia (LID). Numerous research has reported that continuous dopamine delivery (CDD) was useful in reducing the severity of LID. 6-OHDA lesioned rats were divided into two groups to receive intermittent L-dopa st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wen-Wen, Zhang, Xing-Ru, Lin, Jing-Ya, Zhang, Zeng-Rui, Wang, Zhen, Chen, Si-Yan, Xie, Cheng-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593297/ https://www.ncbi.nlm.nih.gov/pubmed/31275144 http://dx.doi.org/10.3389/fphar.2019.00660

Ejemplares similares

Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats
por: Xie, Cheng-long, et al.
Publicado: (2014)

β-arrestin2 alleviates L-dopa–induced dyskinesia via lower D1R activity in Parkinson’s rats
por: Zhang, Xing-Ru, et al.
Publicado: (2019)

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
por: Yang, Xinxin, et al.
Publicado: (2012)

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats
por: Yang, Xinxin, et al.
Publicado: (2012)

Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease
por: Wan, Ying, et al.
Publicado: (2017)

Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model
por: Kambey, Piniel Alphayo, et al.
Publicado: (2023)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
por: Shin, Keon Sung, et al.
Publicado: (2015)

Effect of L-DOPA/Benserazide on Propagation of Pathological α-Synuclein
por: Shimozawa, Aki, et al.
Publicado: (2019)

Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats
por: Zhang, SuFang, et al.
Publicado: (2014)

The Role of the Subthalamic Nucleus in L-DOPA Induced Dyskinesia in 6-Hydroxydopamine Lesioned Rats
por: Aristieta, Asier, et al.
Publicado: (2012)

PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease
por: Yu, Seong-Jin, et al.
Publicado: (2020)

The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Wu, Na, et al.
Publicado: (2018)

Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias
por: Gan, Caiting, et al.
Publicado: (2020)

Targeting the D1-N-methyl-d-aspartate receptor complex reduces l-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Song, Lu, et al.
Publicado: (2016)

Esophageal Atresia in a Newborn Born to a Parkinson's Mother Had L-Dopa/Benserazide Treatment during Pregnancy
por: Hamamcı, Mehmet, et al.
Publicado: (2019)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Altered dynamic functional network connectivity in levodopa‐induced dyskinesia of Parkinson's disease
por: Si, Qianqian, et al.
Publicado: (2022)

Long-term Levodopa Treatment Accelerates the Circadian Rhythm Dysfunction in a 6-hydroxydopamine Rat Model of Parkinson's Disease
por: Li, Si-Yue, et al.
Publicado: (2017)

Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®
por: Gasser, Urs E, et al.
Publicado: (2013)

Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats
por: Alirezaei, Masoud
Publicado: (2015)

Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease
por: Athulya, RT, et al.
Publicado: (2020)

Carnosic Acid Alleviates Levodopa-Induced Dyskinesia and Cell Death in 6-Hydroxydopamine-lesioned Rats and in SH-SY5Y Cells
por: Lai, Chun-Yi, et al.
Publicado: (2021)

3D Printed Mini-Floating-Polypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy
por: Windolf, Hellen, et al.
Publicado: (2022)

Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson’s disease
por: Yang, Yifan, et al.
Publicado: (2023)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Cerebellar connectivity in Parkinson's disease with levodopa‐induced dyskinesia
por: Yoo, Han Soo, et al.
Publicado: (2019)

Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease
por: Teng, Long, et al.
Publicado: (2014)

Effects of mGluR5 Antagonists on Parkinson's Patients With L-Dopa-Induced Dyskinesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wang, Wen-Wen, et al.
Publicado: (2018)

The acute brain response to levodopa heralds dyskinesias in Parkinson disease
por: Herz, Damian M., et al.
Publicado: (2014)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
por: Kwon, Destany K., et al.
Publicado: (2022)

Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson’s disease
por: Cui, Guiyun, et al.
Publicado: (2013)

Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson’s Disease
por: Song, Tianbin, et al.
Publicado: (2021)

Brain-Region Specific Metabolic Abnormalities in Parkinson’s Disease and Levodopa-Induced Dyskinesia
por: Yang, Changwei, et al.
Publicado: (2020)

Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
por: Baufreton, Jérôme, et al.
Publicado: (2018)

Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia
por: Wang, Qiang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t6o9jh96sf6tau61osaj0q42r5